The nomination highlights the transition of the company’s flagship technology, MediChip, from development into clinical validation. The platform utilizes 3D-printed, slow-release delivery designed to attach directly to tissue, aiming to concentrate chemotherapy within the tumor microenvironment while minimizing systemic side effects. By localizing the treatment, the company intends to reduce the total drug dosage required and potentially spare patients from invasive surgeries.
Selection committees for the Prix Galien—which include Nobel laureates and executives from pharmaceutical giants like Merck, Pfizer, and Sanofi—evaluate thousands of applications to identify technologies with the greatest potential to advance human health. For BioSapien, the recognition arrives as the firm prepares to initiate its first-in-human dosing, beginning with clinical trials for colorectal cancer patients in the UAE.
Dr. Khatija Ali, CEO and founder, noted that the company’s objective remains the improvement of patient quality of life during treatment. The final winners will be revealed on October 29, 2026, during a ceremony at the American Museum of Natural History in New York City.
Comments (0)
No comments yet. Be the first!